Increase of interferon-γ inducible α chemokine CXCL10 but not β chemokine CCL2 serum levels in chronic autoimmune thyroiditis
Increase of interferon-γ inducible α chemokine CXCL10 but not β chemokine CCL2 serum levels in chronic autoimmune thyroiditis
复制标题
DOI：
10.1530/eje.1.01847
复制
发表时间：
2005-02-01
影响因子：
5.8
通讯作者：
Serio, M
中科院分区：
文献类型：
--
作者：
Antonelli, A;Rotondi, M;Serio, M
目的：测量新诊断的慢性自身免疫性甲状腺炎（AT）患者的两个主要亚类（CXC 和 CC）的 CXCL10 和 CCL2 原型趋化因子的血清水平，并将结果与临床表型联系起来。设计和方法：对 70 名连续新诊断慢性 AT 患者、性别和年龄匹配的健康志愿者 (n = 37) 以及 20 名非毒性多结节性甲状腺肿患者进行血清 CXCL10 和 CCL2 检测，这些患者是从同一地理区域的一般人群中随机抽取的。结果：甲状腺炎患者的 CXCL10 血清水平显着高于对照组或多结节性甲状腺肿患者，而各组之间的 CCL2 水平相当。甲状腺功能减退患者和低回声患者的 CXCL10 水平显着升高（分别为 P = 0.0004 和 P = 0.0001），而 50 岁以上患者和甲状腺功能减退患者的血清 CCL2 水平显着升高（分别为 P = 0.0001 和 P = 0.03）。 CXCL10 和 CCL2 血清水平之间没有相关性。分别研究了 CXCL10 和 CCL2 与 AT 患者临床特征的关系。对 CXCL10 和 CCL2 进行了两个独立的多元线性回归模型，包括年龄、甲状腺体积、促甲状腺激素 (TSH)、FT4、抗甲状腺过氧化物酶 (AbTPO)、低回声模式和血管过多的存在，证明血清 CXCL10 水平与 TSH 相关，独立于其他可能的混杂因素水平 [回归系数 (R.C.) 0.143 置信区间 (C.I.) (0.042-0.245)； P = 0.0059]，而血清 CCL2 仅与年龄显着相关[R.C. 5.412 C.I. (3.838-6.986)； P<0.0001]。结论：我们在一大群新诊断的 AT 患者中获得的结果表明，CXCL10 升高，尤其是患有更具侵袭性疾病的甲状腺功能减退患者，而 AT 中的 CCL2 血清水平正常。
Objective: To measure serum levels of CXCL10 and CCL2 prototype chemokines of the two major subclass (CXC and CC) in patients with newly diagnosed chronic autoimmume thyroiditis (AT), and relate the findings to the clinical phenotype. Design and methods: Serum CXCL10 and CCL2 were assayed in 70 consecutive patients with newly diagnosed chronic AT, in sex- and age-matched healthy volunteers (n = 37) and in 20 patients with non-toxic multinodular goiter, extracted from a random sample of the general population from the same geographic area. Results: CXCL10 serum levels were significantly higher in patients with thyroiditis than in controls or multinodular goiter patients, while comparable CCL2 levels were found between groups. CXCL10 levels were significantly increased in hypothyroid patients and in those with an hypoechoic pattern (P = 0.0004 and P = 0.0001, respectively) while serum CCL2 levels were significantly increased in patients older than 50 years and in those with hypothyroidism (P = 0.0001 and P = 0.03, respectively). No correlation between CXCL10 and CCL2 serum levels could be demonstrated. CXCL10 and CCL2 were studied separately in relation to clinical features of AT patients. Two separate multiple linear regression models for CXCL10 and CCL2 were performed, including age, thyroid volume, thyroid stimulating hormone (TSH), FT4, anti-thyroid peroxidase (AbTPO), hypoechoic pattern, and the presence of hypervascularity, demonstrating that In of serum CXCL10 levels was associated with TSH independently of other possible confounders levels [regression coefficient (R.C.) 0.143 confidence interval (C.I.) (0.042-0.245); P = 0.0059], while serum CCL2 were significantly associated only with age [R.C. 5.412 C.I. (3.838-6.986); P < 0.0001]. Conclusion: Our results, obtained in a large cohort of newly diagnosed AT patients demonstrate increased CXCL10 especially in hypothyroid patients with a more aggressive disorder, and normal CCL2 serum levels in AT.